Development of Novel Immunotherapies for Multiple Myeloma
AbstractMultiple myeloma (MM) is a disorder of terminally differentiated plasma cells characterized by clonal expansion in the bone marrow (BM). It is the second-most common hematologic malignancy. Despite significant advances in therapeutic strategies, MM remains a predominantly incurable disease emphasizing the need for the development of new treatment regimens. Immunotherapy is a promising treatment modality to circumvent challenges in the management of MM. Many novel immunotherapy strategies, such as adoptive cell therapy and monoclonal antibodies, are currently under investigation in clinical trials, with some already demonstrating a positive impact on patient survival. In this review, we will summarize the current standards of care and discuss major new approaches in immunotherapy for MM. View Full-Text
Share & Cite This Article
Al-Hujaily, E.M.; Oldham, R.A.A.; Hari, P.; Medin, J.A. Development of Novel Immunotherapies for Multiple Myeloma. Int. J. Mol. Sci. 2016, 17, 1506.
Al-Hujaily EM, Oldham RAA, Hari P, Medin JA. Development of Novel Immunotherapies for Multiple Myeloma. International Journal of Molecular Sciences. 2016; 17(9):1506.Chicago/Turabian Style
Al-Hujaily, Ensaf M.; Oldham, Robyn A.A.; Hari, Parameswaran; Medin, Jeffrey A. 2016. "Development of Novel Immunotherapies for Multiple Myeloma." Int. J. Mol. Sci. 17, no. 9: 1506.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.